177 related articles for article (PubMed ID: 34722273)
1. Development and Characterization of a Novel Non-Lytic Cancer Immunotherapy Using a Recombinant Arenavirus Vector Platform.
Lauterbach H; Schmidt S; Katchar K; Qing X; Iacobucci C; Hwang A; Schlienger K; Berka U; Raguz J; Ahmadi-Erber S; Schippers T; Stemeseder F; Pinschewer DD; Matushansky I; Orlinger KK
Front Oncol; 2021; 11():732166. PubMed ID: 34722273
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of two phylogenetically distant arenavirus vectors for the development of novel immunotherapeutic combination strategies for cancer treatment.
Raguz J; Pinto C; Pölzlbauer T; Habbeddine M; Rosskopf S; Strauß J; Just V; Schmidt S; Bidet Huang K; Stemeseder F; Schippers T; Stewart E; Jez J; Berraondo P; Orlinger KK; Lauterbach H
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38631709
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of LCMV-based cancer immunotherapies is unleashed by intratumoral injections of polyI:C.
Gomar C; Di Trani CA; Bella A; Arrizabalaga L; Gonzalez-Gomariz J; Fernandez-Sendin M; Alvarez M; Russo-Cabrera JS; Ardaiz N; Aranda F; Schippers T; Quintero M; Melero I; Orlinger KK; Lauterbach H; Berraondo P
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38631714
[TBL] [Abstract][Full Text] [Related]
4. Alternating Arenavirus Vector Immunization Generates Robust Polyfunctional Genotype Cross-Reactive Hepatitis B Virus-Specific CD8 T-Cell Responses and High Anti-Hepatitis B Surface Antigen Titers.
Schmidt S; Mengistu M; Daffis S; Ahmadi-Erber S; Deutschmann D; Grigoriev T; Chu R; Leung C; Tomkinson A; Uddin MN; Moshkani S; Robek MD; Perry J; Lauterbach H; Orlinger K; Fletcher SP; Balsitis S
J Infect Dis; 2024 Apr; 229(4):1077-1087. PubMed ID: 37602681
[TBL] [Abstract][Full Text] [Related]
5. Live-attenuated lymphocytic choriomeningitis virus-based vaccines for active immunotherapy of HPV16-positive cancer.
Schmidt S; Bonilla WV; Reiter A; Stemeseder F; Kleissner T; Oeler D; Berka U; El-Gazzar A; Kiefmann B; Schulha SC; Raguz J; Habbeddine M; Scheinost M; Qing X; Lauterbach H; Matushansky I; Pinschewer DD; Orlinger KK
Oncoimmunology; 2020 Sep; 9(1):1809960. PubMed ID: 33457095
[TBL] [Abstract][Full Text] [Related]
6. Heterologous arenavirus vector prime-boost overrules self-tolerance for efficient tumor-specific CD8 T cell attack.
Bonilla WV; Kirchhammer N; Marx AF; Kallert SM; Krzyzaniak MA; Lu M; Darbre S; Schmidt S; Raguz J; Berka U; Vincenti I; Pauzuolis M; Kerber R; Hoepner S; Günther S; Magnus C; Merkler D; Orlinger KK; Zippelius A; Pinschewer DD
Cell Rep Med; 2021 Mar; 2(3):100209. PubMed ID: 33763654
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer.
Aggarwal C; Cohen RB; Morrow MP; Kraynyak KA; Sylvester AJ; Knoblock DM; Bauml JM; Weinstein GS; Lin A; Boyer J; Sakata L; Tan S; Anton A; Dickerson K; Mangrolia D; Vang R; Dallas M; Oyola S; Duff S; Esser M; Kumar R; Weiner D; Csiki I; Bagarazzi ML
Clin Cancer Res; 2019 Jan; 25(1):110-124. PubMed ID: 30242022
[TBL] [Abstract][Full Text] [Related]
8. Adenovirus vector-based prime-boost vaccination via heterologous routes induces cervicovaginal CD8
Çuburu N; Khan S; Thompson CD; Kim R; Vellinga J; Zahn R; Lowy DR; Scheper G; Schiller JT
Int J Cancer; 2018 Apr; 142(7):1467-1479. PubMed ID: 29159802
[TBL] [Abstract][Full Text] [Related]
9. Radioimmunotherapy of experimental head and neck squamous cell carcinoma (HNSCC) with E6-specific antibody using a novel HPV-16 positive HNSCC cell line.
Harris M; Wang XG; Jiang Z; Goldberg GL; Casadevall A; Dadachova E
Head Neck Oncol; 2011 Feb; 3(1):9. PubMed ID: 21314983
[TBL] [Abstract][Full Text] [Related]
10. Impaired antigen presentation and effectiveness of combined active/passive immunotherapy for epithelial tumors.
Matsumoto K; Leggatt GR; Zhong J; Liu X; de Kluyver RL; Peters T; Fernando GJ; Liem A; Lambert PF; Frazer IH
J Natl Cancer Inst; 2004 Nov; 96(21):1611-9. PubMed ID: 15523090
[TBL] [Abstract][Full Text] [Related]
11. CD8
Masterson L; Lechner M; Loewenbein S; Mohammed H; Davies-Husband C; Fenton T; Sudhoff H; Jani P; Goon P; Sterling J
Eur J Cancer; 2016 Nov; 67():141-151. PubMed ID: 27669501
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine.
Smalley Rumfield C; Pellom ST; Morillon Ii YM; Schlom J; Jochems C
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554612
[TBL] [Abstract][Full Text] [Related]
13. Isolation and Characterization of an HLA-DRB1*04-Restricted HPV16-E7 T Cell Receptor for Cancer Immunotherapy.
Mercier-Letondal P; Marton C; Deschamps M; Ferrand C; Vauchy C; Chenut C; Baguet A; Adotévi O; Borg C; Galaine J; Godet Y
Hum Gene Ther; 2018 Oct; 29(10):1202-1212. PubMed ID: 30136612
[TBL] [Abstract][Full Text] [Related]
14. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
15. CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies.
Quayle SN; Girgis N; Thapa DR; Merazga Z; Kemp MM; Histed A; Zhao F; Moreta M; Ruthardt P; Hulot S; Nelson A; Kraemer LD; Beal DR; Witt L; Ryabin J; Soriano J; Haydock M; Spaulding E; Ross JF; Kiener PA; Almo S; Chaparro R; Seidel R; Suri A; Cemerski S; Pienta KJ; Simcox ME
Clin Cancer Res; 2020 Apr; 26(8):1953-1964. PubMed ID: 31964784
[TBL] [Abstract][Full Text] [Related]
16. Enhancing antitumor immunogenicity of HPV16-E7 DNA vaccine by fusing DNA encoding E7-antigenic peptide to DNA encoding capsid protein L1 of Bovine papillomavirus.
Yang A; Peng S; Farmer E; Zeng Q; Cheng MA; Pang X; Wu TC; Hung CF
Cell Biosci; 2017; 7():46. PubMed ID: 28852471
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic immunization and local low-dose tumor irradiation, a reinforcing combination.
Draghiciu O; Walczak M; Hoogeboom BN; Franken KL; Melief KJ; Nijman HW; Daemen T
Int J Cancer; 2014 Feb; 134(4):859-72. PubMed ID: 23922012
[TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.
Bellone S; El-Sahwi K; Cocco E; Casagrande F; Cargnelutti M; Palmieri M; Bignotti E; Romani C; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
J Virol; 2009 Jul; 83(13):6779-89. PubMed ID: 19386711
[TBL] [Abstract][Full Text] [Related]
19. Systemic and local human papillomavirus 16-specific T-cell immunity in patients with head and neck cancer.
Heusinkveld M; Goedemans R; Briet RJ; Gelderblom H; Nortier JW; Gorter A; Smit VT; Langeveld AP; Jansen JC; van der Burg SH
Int J Cancer; 2012 Jul; 131(2):E74-85. PubMed ID: 22020783
[TBL] [Abstract][Full Text] [Related]
20. GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth.
Esquerré M; Momot M; Goubier A; Gonindard C; Leung-Theung-Long S; Misseri Y; Bissery MC
Vaccine; 2017 Mar; 35(11):1509-1516. PubMed ID: 28196735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
